ASH 2024 | Dr. Minghui Duan: Exploring the Combination of Selinexor and Ruxolitinib in Myelofibrosis Treatment
From December 7 to 10, 2024, the 66th American Society of Hematology (ASH) Annual Meeting took place in San Diego, USA, bringing together global experts to discuss the latest advancements in hematology. During this prestigious event, Dr. Minghui Duan from Peking Union Medical College Hospital presented his team’s latest findings on myelofibrosis (MF) treatment (Abstract #1002), offering new perspectives for future therapeutic strategies. To provide deeper insights, Hematology Frontier invited Professor Duan for an in-depth discussion on his research.
ASH 2024 | Professor Jerald Radich：Mutations and Minimal Residual Disease (MRD): Clinical Implications of Clonal Origins
Minimal residual disease (MRD) is a powerful predictor of relapse in acute myeloid leukemia (AML), yet its accuracy remains a challenge. Some patients who are MRD-positive do not relapse, while others who are MRD-negative still experience disease recurrence. At the 2024 American Society of Hematology (ASH) Annual Meeting, Professor Jerald Radich from Fred Hutchinson Cancer Center provided an in-depth analysis of how mutations, clonal architecture, and disease evolution influence treatment response, resistance, and relapse.To clarify the complex relationship between MRD and clonal dynamics, Hematology Frontier has compiled key insights from this discussion.
ASH 2024 | Dr. Zhitao Ying: Real-World Data and Implications of CD19 CAR-T Therapy for r/r DLBCL
From December 7 to 10, 2024, the 66th American Society of Hematology (ASH) Annual Meeting took place in San Diego, USA, where global experts gathered to discuss the latest advancements…
ASH 2024 | Dr. Huanling Zhu on Key Advances in Chronic Myeloid Leukemia (CML): Innovations in Therapy and Biomarker Exploration for Treatment-Free Remission
From December 7 to 10, 2024, the 66th American Society of Hematology (ASH) Annual Meeting convened in San Diego, bringing together global hematology experts to discuss the latest advancements in…
ASH 2024 | Dr. Fengkui Zhang and Dr. Bing Han Latest Advances in the First-in-Class Bifunctional C5 Antibody/Factor H Fusion Protein for PNH Treatment
From December 7 to 10, 2024, the 66th American Society of Hematology (ASH) Annual Meeting took place in San Diego, USA, where leading experts in hematology gathered to discuss the…
2024 CCHIO & CACA 40th Anniversary: A Landmark Event in Cancer Prevention and Treatment
On November 14, 2024, the 2024 Chinese Congress on Holistic Integrative Oncology (CCHIO) and the 40th Anniversary of the China Anti-Cancer Association (CACA) commenced at the Xi’an International Conference Center. Themed “CACA at 40: Carrying Forward and Innovating,” the event brought together medical experts, patient advocates, and leaders from various sectors to advance the fight against cancer.
Professor Jun Ma: Advancing Frontiers, Updating Guidelines, and Accelerating the Globalization of Hematologic Cancer Treatment
From January 17 to 19, 2025, the Chinese Society of Clinical Oncology (CSCO) Leukemia, Lymphoma, and Multiple Myeloma Expert Committee Meeting & 2025 CSCO Hematologic Oncology Conference was held in the scenic city of Haikou. This high-profile event brought together leading experts from China and abroad to discuss the latest advances in leukemia, lymphoma, and multiple myeloma, covering both fundamental research and clinical applications. The conference also addressed key challenges in diagnosis and treatment, fostering in-depth discussions among specialists.
Sequential CD20 CAR-T Therapy is Superior to Salvage Chemotherapy in B-cell Lymphoma Patients with CD19 CAR-T Treatment Failure
In recent years, with the application of CD19 CAR-T in refractory/relapsed B-cell lymphoma, we have encountered patients for whom CD19 CAR-T treatment is ineffective or those who relapse after a brief period of effectiveness. Beyond exploring factors that may affect the efficacy of CD19 CAR-T therapy, many doctors and researchers are actively seeking effective treatments for these patients. In June this year, Dr. Xiaoyan Ke and Dr. Kai Hu's team from Beijing GoBroad Boren Hospital published an article titled “Salvage CD20-SD-CART therapy in aggressive B-cell lymphoma after CD19 CART treatment failure” in the Frontiers in Oncology, providing new insights into treatment options for B-cell lymphoma patients who have failed CD19 CAR-T therapy.